Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for EfficacyPRNewsWire • 11/09/23
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCPRNewsWire • 11/03/23
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational HighlightsPRNewsWire • 11/03/23
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMOPRNewsWire • 10/23/23
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET StudyPRNewsWire • 10/23/23
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational HighlightsPRNewsWire • 10/20/23
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023PRNewsWire • 10/16/23
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTSPRNewsWire • 09/26/23
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare ConferencePRNewsWire • 09/19/23
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/06/23
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)Zacks Investment Research • 08/17/23
Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational HighlightsPRNewsWire • 08/14/23
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth ConferencePRNewsWire • 08/04/23
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational HighlightsPRNewsWire • 08/04/23
Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trialMarket Watch • 06/22/23
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform TrialPRNewsWire • 06/22/23
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response RatePRNewsWire • 06/05/23
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual MeetingPRNewsWire • 05/26/23
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting AbstractPRNewsWire • 05/25/23
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersPRNewsWire • 05/10/23